Completed PHASE1 INTERVENTIONAL 1-arm NCT00978913

Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma

Evaluation of Dendritic Cells Transfected With Survivin, hTERT and p53 mRNA as a Treatment for Patients With Metastatic Breast Cancer or Malignant Melanoma

Sponsor: Inge Marie Svane

Conditions Breast Cancer Malignant Melanoma

Interventions DC vaccine

Updated 5 times since 2017 Last updated: Aug 18, 2015 Started: Sep 30, 2009 Primary completion: Aug 31, 2013 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Breast Cancer and Malignant Melanoma, this trial is completed. The trial is conducted by Inge Marie Svane and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inge Marie Svane

Data source: Herlev Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herlev, Denmark